ArticleDiscover oncology2025
Prognostic factors and nomogram for intracranial malignant meningeal sarcomatosis: a population-based retrospective surveillance, epidemiology, and end results database analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracranial Meningeal Sarcomatosis (MS) is a rare neoplasm of the central nervous system (CNS), characterized by diagnostic challenges and a poor prognosis. This study aimed to utilize Surveillance, Epidemiology, and End Results (SEER) population data to identify prognostic factors and develop a nomogram for overall survival (OS) in patients with intracranial malignant MS between 2000 and 2021.
methodsData of 43 patients diagnosed with malignant MS extracted from the SEER registry from 2000 to 2021 were analyzed. Univariate and multivariable Cox regression analyses were performed to examine factors influencing OS. Nomogram for predicting 1-, 3-, 5- years overall survival probability was created based on the multivariate Cox regression model. Additionally, a literature review of intracranial MS was carried out.
resultsA total of 43 patients with malignant MS, spanning all ages, were identified from 2000 to 2021. The gender distribution was 62.8% female (27 patients) and 37.2% male (16 patients). White patients constituted 67.4% of the cohort, and Spanish-Hispanic-Latino patients made up 93% of the total population. Five variables (age, sex, grade, total number of in situ/malignant tumors, surgical resection combined radiation) were brought into multivariate Cox regression to identify the independent prognostic factors for OS. A comprehensive model was developed utilizing four predictors identified through multivariate Cox regression analysis. Additionally, there were 13 literatures accessible with intracranial MS in previous studies for review.
conclusionThis SEER study identifies important prognostic factors for malignant MS. While suggesting benefits of comprehensive treatment, the findings are limited by sample size and require validation in larger, prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.